Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Genetic Testing

DNAAF1 Gene Primary Ciliary Dyskinesia Type 13 Genetic Test

This genetic test identifies mutations in the DNAAF1 gene, which can cause Primary Ciliary Dyskinesia (PCD), a condition affecting the cilia in the respiratory system. It helps diagnose chronic respiratory and ENT issues.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A blood sample is required for this test. Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. However, confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the DNAAF1 Gene Primary Ciliary Dyskinesia Type 13 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected Primary Ciliary Dyskinesia (PCD)
  • ✓Chronic respiratory infections (e.g., bronchitis, pneumonia)
  • ✓Persistent wet cough
  • ✓Recurrent sinusitis
  • ✓Chronic otitis media (middle ear infections)
  • ✓Situs inversus (organs reversed)
  • ✓Family history of PCD
  • ✓Infertility in males (related to sperm motility)
02

In plain language

What this test helps you understand

This test helps confirm a diagnosis of Primary Ciliary Dyskinesia (PCD) caused by mutations in the DNAAF1 gene. It can aid in understanding the specific genetic cause of a patient's symptoms, which may inform treatment strategies and prognosis. It can also be used for carrier screening in families with a history of PCD.
This test is used to detect mutations in the DNAAF1 gene, which are associated with Primary Ciliary Dyskinesia (PCD). PCD is a rare, inherited disorder that affects the function of cilia, the tiny hair-like structures lining the airways, ears, and other parts of the body. These cilia are responsible for moving mucus and debris out of the lungs and sinuses. When cilia don't function properly due to genetic mutations, it can lead to chronic respiratory infections, persistent cough, sinusitis, ear infections, and other related health problems. This test uses Next Generation Sequencing (NGS) technology to analyze the DNAAF1 gene for specific changes. Understanding the genetic basis of PCD can help guide diagnosis, management, and family planning.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. However, confirm with the laboratory before booking.
SampleA blood sample is required for this test. Confirm with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze the DNAAF1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only analyzes the DNAAF1 gene. PCD can be caused by mutations in other genes. A negative result does not completely rule out PCD. This test may not detect all possible mutations within the DNAAF1 gene. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

PCD is a rare genetic disorder where the cilia, tiny hair-like structures in the body, don't work properly. This affects the lungs, ears, sinuses, and sometimes other organs.
This test specifically looks for mutations (changes) in the DNAAF1 gene, which is one of the genes that can cause PCD.
People with symptoms like chronic lung infections, persistent cough, recurrent ear or sinus infections, or a family history of PCD might be advised to take this test.
A blood sample is needed for this test. We offer sample collection at our labs or potentially at home; please confirm availability.
Your results will be analyzed by specialists. If mutations are found, your doctor will discuss the implications and next steps with you.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test

The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.

Learn more →

Bcell Rearrangement Detection Test

The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.

Learn more →

Dpd Gene Mutations 5Fu Toxicity Detection Test

This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).

Learn more →

Ganciclovir Resistance Detection Test

This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.

Learn more →
Chat on WhatsApp